Evidence map›Paper›PMID 42667368›Full record

ArticleCancer chemotherapy and pharmacology2026

Safety and preliminary efficacy results of a new micellar formulation of docetaxel in patients with metastatic castration-resistant prostate cancer - SAKK 67/20 trial.

Ilaria Colombo, Pascale C S Rietveld, Stefanie Fischer, Stefania Merlo, Ursula Vogl, Richard Cathomas, Stijn L W Koolen, Daniela Zoelly, Katrin Gobat, Charlotte Micheloud and 5 more

Registry-linked trialAbstract readClinical Trial, Phase I
PubMed Publisher
In one paragraph

Article in Cancer chemotherapy and pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04629781 (Open-label Dose Escalation Phase 1b Trial of a New Micellar Docetaxel Compound in Patients With Metastatic Castration-resistant Prostate Cancer), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04629781 phase1terminatednot on this map

Open-label Dose Escalation Phase 1b Trial of a New Micellar Docetaxel Compound in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC)

TypeinterventionalSponsorSwiss Cancer InstituteRan2021 to 2024Enrolled11ConditionsMetastatic Castration-resistant Prostate CancerArmsDocetaxel micellar
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Ilaria ColomboMedical Oncology, Oncology Institute of Southern Switzerland (IOSI), EOC, Bellinzona, Switzerland.
Pascale C S RietveldDepartment of Medical Oncology and Hospital Pharmacy, Erasmus MC Cancer Institute, Rotterdam, Netherlands.
Stefanie FischerDepartment of Medical Oncology and Hematology, Kantonsspital, Health Ostschweiz (HOCH), Rorschacherstrasse 95, St. Gallen, CH-9007, Switzerland.
Stefania MerloDivision of Oncology and Hematology, Kantonsspital Graubünden, Chur, Switzerland.
Ursula VoglMedical Oncology, Oncology Institute of Southern Switzerland (IOSI), EOC, Bellinzona, Switzerland.
Richard CathomasDivision of Oncology and Hematology, Kantonsspital Graubünden, Chur, Switzerland.
Stijn L W KoolenDepartment of Medical Oncology and Hospital Pharmacy, Erasmus MC Cancer Institute, Rotterdam, Netherlands.
Daniela ZoellyCompetence Center of Swiss Cancer Institute (SCI), Bern, Switzerland.
Katrin GobatCompetence Center of Swiss Cancer Institute (SCI), Bern, Switzerland.
Charlotte MicheloudCompetence Center of Swiss Cancer Institute (SCI), Bern, Switzerland.
Katrin EckhardtCompetence Center of Swiss Cancer Institute (SCI), Bern, Switzerland.
Cristiana SessaMedical Oncology, Oncology Institute of Southern Switzerland (IOSI), EOC, Bellinzona, Switzerland.
Anastasios StathisMedical Oncology, Oncology Institute of Southern Switzerland (IOSI), EOC, Bellinzona, Switzerland.
Aurelius OmlinMedical Oncology and Haematology Department, OnkoZentrum Zürich, Zurich, Switzerland.
Markus JoergerDepartment of Medical Oncology and Hematology, Kantonsspital, Health Ostschweiz (HOCH), Rorschacherstrasse 95, St. Gallen, CH-9007, Switzerland. Markus.joerger@h-och.ch.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeDocetaxel micellar (DM) is a novel polysorbate-free docetaxel formulation that does not require steroid premedication. The aim of this study was to define the safety, pharmacokinetics (PK) and preliminary activity of DM in patients with metastatic castration-resistant prostate cancer (mCRPC).

methodsDM was administered intravenously to chemotherapy-naïve patients with mCRPC every 3 weeks following a 3 + 3 design (75, 90, 100 mg/m

resultsA total of 11 patients were recruited from June 2021 to April 2023. No dose limiting toxicities (DLT) were observed at 75 or 90 mg/m

conclusionsSteroid-free 3-weekly DM at a dose of 90 mg/m2 was not associated with DLT. Preliminary activity of DM appeared consistent with historical outcomes reported for conventional docetaxel in patients with mCRPC (NCT04629781).

Indexed as

Antineoplastic AgentsDocetaxelProstatic Neoplasms, Castration-ResistantAgedDose-Response Relationship, DrugHumansMaleMaximum Tolerated DoseMicellesMiddle AgedAntineoplastic AgentsDocetaxelMicellesDocetaxel micellarMetastatic castration-resistant prostate cancerPhase 1 dose-escalationProstate cancerSteroid-free chemotherapy

Identifiers

PMID42667368

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.